Minrad International reduces workforce
This reduction in workforce will affect positions in company locations including Pennsylvania, New York and other geographies. Dave DiGiacinto, president and COO, said: “We have taken this difficult,
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).
The Infectious Disease Research Institute (IDRI) retains worldwide exclusive rights to glycopyranosyl lipid adjuvant (GLA) for selected diseases affecting predominately the developing world. Under the agreement, IDRI will